Skip to main content

Gilead disputes report that its drug flopped in leaked coronavirus trial

(ITNTV) - A closely-watched Gilead Sciences Inc (GILD.O) experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China, but the drugmaker said the findings were inconclusive because the study was terminated early.
Gilead shares closed down 4.3% after the data was inadvertently released and first reported by the Financial Times. It comes days after another report detailed rapid recovery in fever and respiratory symptoms in some patients with COVID-19 - the sometimes deadly respiratory illness caused by the coronavirus - who were treated with remdesivir at the University of Chicago Medicine hospital.
Interest in Gilead’s remdesivir has been high as there are currently no approved treatments or preventive vaccines for COVID-19, and doctors are desperate for anything that might alter the course of the disease that attacks the lungs and can shut down other organs in extremely severe cases.
In the Chinese trial remdesivir, given by intravenous infusion, failed to improve patients’ condition or reduce the pathogen’s presence in the bloodstream, according to draft documents published accidentally by the World Health Organization (WHO).
But details were thin and suggested limitations in interpreting the data that has not yet been fully reviewed.
A screenshot of the WHO posting, captured by the medical news website STAT before it was taken down, said the trial enrolled 237 patients with 158 receiving remdesivir compared with 79 who got a placebo.
The rate of death was similar at 13.9% for remdesivir versus 12.8% in the control group.
“It’s still not that large of a study and therefore the statistics coming out of the trial aren’t exactly robust,” Mizuho analyst Salim Syed said in a research note.
ADVERTISEMENT
Gilead in a statement said the WHO posting included inappropriate characterizations of the study, which was terminated early due to low enrollment and, as a result, cannot be used to make statistically meaningful conclusions.
“The study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the company said without providing details to back up that assertion.
Doctors have speculated that an antiviral drug like remdesivir would likely be most effective when administered as early as possible in the course of the disease as it is designed to help keep the virus from replicating in the blood.
“You can put out a campfire, but once it becomes a wildfire it’s hard to control,” said Dr. Kevin Grimes, an infectious disease specialist at Houston Methodist Hospital who was not involved in the study.
The WHO said the draft manuscript is undergoing peer review before it will be officially released.
David Katz, chief investment officer at Matrix Asset Advisors, which owns Gilead shares, noted that multiple clinical studies remained ongoing for remdesivir and said, “we would not be selling (the stock) into weakness today.”
Gilead is awaiting results of a trial of remdesivir, which previously failed as an Ebola treatment, in 400 patients hospitalized with severe COVID-19, with data expected later this month.
A separate trial in China testing the drug in patients with more moderate symptoms last week was also suspended due to a lack of eligible patients.
Brad Loncar, whose Loncar Investments runs a cancer immunotherapy ETF, was not ready to draw conclusions from the latest China data.
“Just as it was too much of a reach to be optimistic about positive anecdotes we have heard, I think it’s too pessimistic to write it off based on this (incomplete) data.”

Comments

Post a Comment

Popular posts from this blog

European Union will close its borders to all non-essential travel to fight coronavirus

Madrid (ITNTV) The European Union will close its borders to all non-essential travel as it attempts to contain the  ongoing spread of the coronavirus  on the continent. "The less travel, the more we can contain the virus," European Commission President Ursula von der Leyen said Monday following a video conference between G7 leaders. She appeared confident that the European Council would sign off on the restriction in a Tuesday vote. The bloc's member states imposed aggressive measures on Monday,  days after the  World Health Organization (WHO) said Europe was at the epicenter of the pandemic. French President Emmanuel Macron declared "war" on the virus during a national address on Monday, banning all social events across the country -- including family gatherings. Macron said those who have gathered in public places in recent days have not been respecting previous measures to limit the outbreak's spread in France, which as of Monday had 5,380 con...
Post a Comment
Read more

PhD positions: In Institute of Biochemistry, Jena University Hospital - Friedrich Schiller University Jena, Germany

PhD positions: In Institute of Biochemistry, Jena University Hospital - Friedrich Schiller University Jena, Germany   🇩🇪 . Subjects: Neurobiology / Imaging Description: 1 PhD position in Neurobiology / Imaging Prof. Britta Qualmann, Inst. of Biochem. I, UKJ - Friedrich Schiller University Jena, Germany Prof. Christian Geis, Section of Translat. Neuroimmunol., Dept. Neurol., UKJ We seek for a productive addition to our research team in a collaborative project. We plan to study pathomechanisms of synaptic changes underlying autoimmune disorders of the central nervous system applying super-resolution microscopy. The Geis lab examines immune-mediated changes of synapses by interactions with pathogenic human antibodies against neuronal proteins. Short- and long-term effects on neuronal networks are analyzed using electrophysiological and various microscopy methods. The Qualmann lab is an internationally well-known lab that focusses on proteins with the power to s...
Post a Comment
Read more

80 pct of life stopped in Turkey due to outbreak, says interior minister

Turkish citizens, especially those living in metropolises, have been abiding by the “social isolation” principles laid out by the government, Interior Minister  Süleyman Soylu  has said, adding that almost 80 percent of life “stopped” in  Turkey . “Up until now, just our ministry issued 38 circulars, 17 of which concern the borders. Many high-level precautions have been taken. Right now, 80 percent of life stopped in Turkey,” Soylu said on March 26 in an interview with a private broadcaster. Soylu also provided updated figures for passenger traffic. He said that there is a 73 percent decline in inter-city bus services, adding that these services can also be suspended if needed. On intra-city traffic, Soylu said that there has been an 80 percent decline. This figure was 65 percent according to another interview the minister held on March 25. The government has four cruxes it predicates on when taking measures against the spread of the novel  coronaviru...
Post a Comment
Read more